CG Oncology, Inc. (CGON) vs Ligand Pharmaceuticals Incorporated (LGND)
CG Oncology, Inc. and Ligand Pharmaceuticals Incorporated are both Biotechnology companies. CG Oncology, Inc. and Ligand Pharmaceuticals Incorporated are of similar size ($6.1B and $6.1B). CG Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Ligand Pharmaceuticals Incorporated trades at 30.1×. CG Oncology, Inc. grew revenue faster over the last twelve months: 840.8% against 54.9%. Ligand Pharmaceuticals Incorporated has the higher net margin (67.9% vs −3,602.7%) and the higher return on invested capital (8.19% vs −4,111.6%). Across the 17 metrics below, Ligand Pharmaceuticals Incorporated leads on 14 and CG Oncology, Inc. on 3.
Valuation
Profitability
| Metric | CGON | LGND | Biotechnology median |
|---|---|---|---|
| Gross margin | (85.20%) | 95.43% | 65.16% |
| Operating margin | (4,056.18%) | 32.61% | 0.00% |
| Net margin | (3,602.68%) | 67.88% | 0.00% |
| Free cash flow margin | (2,879.62%) | 49.34% | 0.00% |
| Return on equity | (26.41%) | 21.96% | (57.72%) |
| Return on assets | (25.11%) | 12.58% | (49.22%) |
| Return on invested capital | (4,111.64%) | 8.19% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack